# Alemtuzumab to Treat Severe Aplastic Anemia

> **NCT00195624** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 47 (actual)

## Conditions studied

- Severe Aplastic Anemia, Refractory
- Severe Aplastic Anemia, Relapse

## Interventions

- **BIOLOGICAL:** Alemtuzumab (Campath )
- **DRUG:** Cyclosporine

## Key facts

- **NCT ID:** NCT00195624
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09-15
- **Primary completion:** 2014-04-14
- **Final completion:** 2018-10-15
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195624, "Alemtuzumab to Treat Severe Aplastic Anemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00195624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*